The Dawn of a New Era: Emerging Therapeutic Strategies in the Diagnosis and Management of NASH Evaluation (ID: i762b) Survey

Question Title

* 1. After participating in this activity, how confident are you in the management of patients with NASH in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 2. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 3. How many patients with NASH do you manage?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 4. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

VA, DOD or other government

Managed Care

Research

Pharmaceutical industry

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Improved ability to identify NASH

Be better able to stage and monitor NASH using liver biopsy and complimentary noninvasive modalities

Increased understanding of NAFLD/NASH pathophysiology and progression

Expanded knowledge of the safety and efficacy profiles of emerging therapies undergoing clinical development for NASH

Ability to identify patients who may be appropriate candidates for clinical trials

Question Title

* 8. What barriers do you see to making changes in your practice? select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 9. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Identify NASH using current epidemiologic and demographic data	Identify NASH using current epidemiologic and demographic data Strongly agree	Identify NASH using current epidemiologic and demographic data Agree	Identify NASH using current epidemiologic and demographic data Neutral	Identify NASH using current epidemiologic and demographic data Disagree	Identify NASH using current epidemiologic and demographic data Strongly disagree
Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring	Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring Strongly agree	Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring Agree	Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring Neutral	Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring Disagree	Apply liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring Strongly disagree
Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers	Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers Strongly agree	Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers Agree	Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers Neutral	Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers Disagree	Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers Strongly disagree
Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH	Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH Strongly agree	Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH Agree	Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH Neutral	Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH Disagree	Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH Strongly disagree

Question Title

* 10. Steven L. Flamm, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 11. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for NASH or related disease states.

Question Title

* 1. After participating in this activity, how confident are you in the management of patients with NASH in your practice?

Question Title

* 2. How many years have you been in practice?

Question Title

* 3. How many patients with NASH do you manage?

Question Title

* 4. Please select the option that best describes your practice setting.

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? select all that apply.

Question Title

* 9. After participating in today’s activity, I am now able to:

Question Title

* 10. Steven L. Flamm, MD, effectively:

Question Title

* 11. The content presented:

Question Title

* 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for NASH or related disease states.

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe: